Law Offices of Howard G. Smith continues its investigation on behalf of CytoDyn Inc. ("CytoDyn" or the "Company") (OTC: CYDY) investors concerning the Company and its officers’ possible violations of federal securities laws.
On April 27, 2020, CytoDyn issued a press release indicating it had submitted a "Biologics License Application ('BLA') to the U.S. Food and Drug Administration for Leronlimab as a combination therapy with HAART for highly treatment experienced HIV patients."
Then, on May 7, 2020, CytoDyn announced that its BLA for Leronlimab "will be considered completed after the clinical datasets are submitted on May 11, 2020."
On this news, the Company's share price fell as much as $0.225, or more than 7%, during intraday trading on May 8, 2020.
On June 30, 2020, Citron Research issued a report stating, among other things, that despite CytoDyn's "aggressively tout[ing] its investigational drug candidate, Leronlimab, as a potential treatment for COVID-19 . . . there is zero scientific data to support this view."
On this news, the Company's share price fell $3.09, or over 35%, to close at $5.68 per share on June 30, 2020, on unusually heavy trading volume.
If you purchased CytoDyn securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.